Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022. https://doi.org/10.1136/gutjnl-2022-327745.

Article  PubMed  Google Scholar 

Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70:1815–22.

Article  CAS  PubMed  Google Scholar 

Kuo YT, Liou JM, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707–15.

Article  PubMed  Google Scholar 

Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135(24):2899–910. https://doi.org/10.1097/CM9.0000000000002546

Article  PubMed  Google Scholar 

Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am. 2015;44:537–63.

Article  PubMed  PubMed Central  Google Scholar 

Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol. 2016;111:1736–42.

Article  CAS  PubMed  Google Scholar 

Song Z, Suo B, Zhang L, et al. Rabeprazole, minocycline, amoxicillin, and bismuth as first-line and second-line regimens for Helicobacter pylori eradication. Helicobacter. 2016;21:462–70.

Article  CAS  PubMed  Google Scholar 

Song ZQ, Zhou LY. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication. J Dig Dis. 2016;17:260–7.

Article  CAS  PubMed  Google Scholar 

Best LM, Haldane DJ, Keelan M, et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother. 2003;47:3138–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. 2022;Version 12.0: http://www.eucast.org.

Nakajima S, Inoue H, Inoue T, et al. Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy. J Gastroenterol Hepatol. 2012;27(Suppl 3):108–11.

Article  CAS  PubMed  Google Scholar 

Murakami K, Sato R, Okimoto T, et al. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2006;21:262–7.

Article  CAS  PubMed  Google Scholar 

Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-7.e1.

Article  CAS  PubMed  Google Scholar 

Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905–13.

Article  CAS  PubMed  Google Scholar 

Goodwin CS, Marshall BJ, Blincow ED, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988;41:207–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji Y, Lu H. Meta-analysis: high-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS ONE. 2018;13:e0189888.

Article  PubMed  PubMed Central  Google Scholar 

Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–53.

Article  CAS  PubMed  Google Scholar 

Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329–42.

Article  CAS  PubMed  Google Scholar 

Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 1: tetracyclines. Am J Hosp Pharm. 1977;34:49–57.

CAS  PubMed  Google Scholar 

O’Connor JP, Taneike I, O’Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2:273–9.

Article  PubMed  PubMed Central  Google Scholar 

Bai P, Zhou LY, Xiao XM, et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. J Dig Dis. 2015;16:464–70.

Article  CAS  PubMed  Google Scholar 

Zhao J, Zou Y, Li K, et al. Doxycycline and minocycline in Helicobacter pylori treatment: a systematic review and meta-analysis. Helicobacter. 2021;26: e12839.

PubMed  Google Scholar 

Nyssen OP, Perez-Aisa A, Rodrigo L, et al. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter. 2020;25: e12722.

Article  CAS  PubMed  Google Scholar 

Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci. 2019;64:2893–8.

Article  CAS  PubMed  Google Scholar 

Akyildiz M, Akay S, Musoglu A, et al. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med. 2009;20:53–7.

Article  CAS  PubMed  Google Scholar 

Perri F, Festa V, Merla A, et al. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter. 2002;7:99–104.

Article  CAS  PubMed  Google Scholar 

Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999;4:106–12.

Article  CAS  PubMed  Google Scholar 

Borody TJ, George LL, Brandl S, et al. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. Scand J Gastroenterol. 1992;27:281–4.

Article  CAS  PubMed  Google Scholar 

Ierardi E, Giangaspero A, Losurdo G, et al. Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens. J Gastrointestin Liver Dis. 2014;23:367–70.

Article  PubMed  Google Scholar 

Jin Y, Zhang S, Pan J, et al. Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis. Pharmazie. 2019;74:432–8.

CAS  PubMed  Google Scholar 

Zhang L, Zhou L, Song Z, et al. Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection. Zhonghua Nei Ke Za Zhi. 2015;54:1013–7.

CAS  PubMed  Google Scholar 

Jacobson JA, Daniel B. Vestibular reactions associated with minocycline. Antimicrob Agents Chemother. 1975;8:453–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Williams DN, Laughlin LW, Lee YH. Minocycline: Possible vestibular side-effects. Lancet. 1974;2:744–6.

Article  CAS  PubMed  Google Scholar 

Zhang L, Lan Y, Wang Q, et al. Application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of Helicobacter pylori. Gastroenterol Res Pract. 2019;2019:9251879.

Article  PubMed  PubMed Central  Google Scholar 

Ables AZ, Simon I, Melton ER. Update on Helicobacter pylori treatment. Am Fam Physician. 2007;75:351–8.

PubMed  Google Scholar 

Ding YM, Li YY, Liu J, et al. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med 2022. https://doi.org/10.1007/s10238-022-00953-7.

Article  PubMed  Google Scholar 

Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693–5.

Article  CAS  PubMed  Google Scholar 

Freeman E, Ellen RP, Thompson G, et al. Gingival crevicular fluid concentration and side effects of minocycline: a comparison of two dose regimens. J Periodontol. 1992;63:13–8.

Article  CAS  PubMed  Google Scholar